Gain Therapeutics (GANX) said Monday it has received approval in Australia to start a phase 1b trial of GT-02287, the company's lead allosteric small molecule in clinical development to treat Parkinson's disease with or without a GBA1 mutation.
The main objective of the phase 1b trial is to evaluate the safety and tolerability of GT-02287 and follows the completed phase 1 study in healthy volunteers that showed it was safe, well-tolerated and increased glucocerebrosidase activity, the company said.
The company said it expects to complete enrollment for the phase 1b study to be completed in the spring of 2025 and data to be released in the middle of that year.
Shares of Gain Therapeutics were up 17% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。